ArticleEuropean journal of medical research2025
Global, regional, and national burdens of non-rheumatic calcific aortic valve disease in middle-aged and elderly populations from 1990 to 2021 and predictions up to 2050: trends, predictions, and health inequity.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The COPD-augmented R₂CHA₂DS₂-VA score: development and internal assessment for predicting one-year outcomes after transcatheter aortic valve implantation.BMC cardiovascular disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe global incidence of non-rheumatic calcific aortic valve disease (NR-CAVD) is increasing annually owing to changes in the global population structure. We aimed to comprehensively assess the global disease burden and health inequity of NR-CAVD from 1990 to 2021 and predict the situation through 2050.
methodsData on mortality, prevalence, incidence, DALYs, YLDs, and YLLs of NR-CAVD were extracted from the GBD 2021. The Joinpoint model, linear regression model, and health inequity index were used to evaluate the time trends from 1990 to 2021, predict the disease burden through 2050, and decompose NR-CAVD according to population aging, epidemiological changes, and population growth.
resultsFrom 1990 to 2021, the number of incident cases, prevalent cases, disability-adjusted life years (DALYs), and YLDs of NR-CAVD increased in both sexes, whereas the age-standardized rates are projected to decline through 2050. Decomposition analysis identified population growth as the primary driver, followed by aging. Significant health inequity in prevalence was observed across regions with different economic development levels.
conclusionOwing to population aging and growth, the NR-CAVD burden in middle-aged and elderly populations will continue to rise by 2050, with marked health inequity across economically divergent regions, highlighting the need to address this emerging public health challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.